IN8bio

Hand turns a dice and changes the expression half empty to half full

Biotech

IN8bio halts phase 2 trial, lays off half of workforce

The biotech is shifting focus to INB-100, an allogeneic cell therapy being tested in acute myeloid leukemia patients receiving stem cell transplants.

Darren Incorvaia Sep 5, 2024 4:30am

picture of a paraglider

Agios replaces CEO after recent FDA nod—Chutes & Ladders

Jul 15, 2022 9:30am

Nasdaq

After name change and dropped IPO, IN8bio tries again

Apr 2, 2021 8:05am